The endocannabinoids anandamide and virodhamine modulate the activity of the candidate cannabinoid receptor GPR55

Journal of Neuroimmune Pharmacology

Volumn 7, Issue 4, 2012, Pages 856-865

  Sharir, Haleli ^a   Console Bram, Linda ^a   Mundy, Christina ^a   Popoff, Steven N ^a   Kapur, Ankur ^a   Abood, Mary E ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anandamide; Endocannabinoids; GPCR; GPR55; Virodhamine

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; ANANDAMIDE; BETA ARRESTIN 2; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABINOID RECEPTOR; CANNABINOID RECEPTOR GPR55; GREEN FLUORESCENT PROTEIN; LACTATE DEHYDROGENASE; RIMONABANT; UNCLASSIFIED DRUG; VIRODHAMINE;

ARTICLE; CELL DAMAGE; CELL DEATH; CELL VIABILITY; CONCENTRATION RESPONSE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DRUG ACTIVITY; HUMAN; HUMAN CELL; IC 50; IMMUNOCYTOCHEMISTRY; IN VITRO STUDY; INFLAMMATION; INTERNALIZATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; SIGNAL TRANSDUCTION;

ANIMALS; ARACHIDONIC ACIDS; ARRESTINS; CANNABINOID RECEPTOR AGONISTS; CANNABINOID RECEPTOR MODULATORS; CANNABINOIDS; CELL LINE; CELL SURVIVAL; CHO CELLS; CRICETINAE; CRICETULUS; ENDOCANNABINOIDS; GREEN FLUORESCENT PROTEINS; HEK293 CELLS; HUMANS; IMMUNOHISTOCHEMISTRY; L-LACTATE DEHYDROGENASE; MICROSCOPY, CONFOCAL; POLYUNSATURATED ALKAMIDES; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2; RECEPTORS, G-PROTEIN-COUPLED; RNA;

EID: 84875841356     PISSN: 15571890     EISSN: 15571904     Source Type: Journal    
DOI: 10.1007/s11481-012-9351-6     Document Type: Article

References (36)

1. Abood ME, Rizvi G, Sallapudi N, McAllister SD (2001) Activation of the CB1 cannabinoid receptor protects cultured mouse spinal neurons against excitotoxicity. Neurosci Lett 309(3):197-201
2. Anavi-Goffer S, Baillie G, Irving AJ, Gertsch J, Greig IR, Pertwee RG, Ross RA (2012) Modulation of L-alpha-Lysophosphatidylinositol/GPR55 Mitogen-activated Protein Kinase (MAPK) Signaling by Cannabinoids. J Biol Chem 287(1):91-104. doi: 10.1074/jbc.M111.296020
3. Andradas C, Caffarel MM, Perez-Gomez E, Salazar M, Lorente M, Velasco G, Guzman M, Sanchez C (2011) The orphan G protein-coupled receptor GPR55 promotes cancer cell proliferation via ERK. Oncogene 30(2):245-252. doi: 10.1038/onc.2010.402
4. Balenga NA, Aflaki E, Kargl J, Platzer W, Schroder R, Blattermann S, Kostenis E, Brown AJ, Heinemann A, Waldhoer M (2011) GPR55 regulates cannabinoid 2 receptor-mediated responses in human neutrophils. Cell Res. doi: 10.1038/cr.2011.60
5. Bondarenko AI, Malli R, Graier WF (2011) The GPR55 agonist lysophosphatidylinositol acts as an intracellular messenger and bidirectionally modulates Ca2+ -activated large-conductance K + channels in endothelial cells. Pflugers Arch 461(1):177-189. doi: 10.1007/s00424-010-0898-x
6. Bonfoco E, Krainc D, Ankarcrona M, Nicotera P, Lipton SA (1995) Apoptosis and necrosis: two distinct events induced, respectively, by mild and intense insults with N-methyl-D-aspartate or nitric oxide/superoxide in cortical cell cultures. Proc Natl Acad Sci U S A 92(16):7162-7166
7. Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, Gibson D, Mandelbaum A, Etinger A, Mechoulam R (1992) Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science (New York, NY) 258:1946-1949
8. Di Marzo V, Melck D, Bisogno T, De Petrocellis L (1998) Endocannabinoids: endogenous cannabinoid receptor ligands with neuromodulatory action. Trends Neurosci 21(12):521-528
9. Ford LA, Roelofs AJ, Anavi-Goffer S, Mowat L, Simpson DG, Irving AJ, Rogers MJ, Rajnicek AM, Ross RA (2010) A role for L-alpha- lysophosphatidylinositol and GPR55 in the modulation of migration, orientation and polarization of human breast cancer cells. Br J Pharmacol 160(3):762-771. doi: 10.1111/j.1476-5381.2010.00743.x
10. Grimsey NL, Goodfellow CE, Dragunow M, Glass M (2011) Cannabinoid receptor 2 undergoes Rab5-mediated internalization and recycles via a Rab11-dependent pathway. Biochim Biophys Acta 1813(8):1554-1560. doi: 10.1016/j.bbamcr.2011.05.010
11. Henstridge CM, Balenga NA, Ford LA, Ross RA, Waldhoer M, Irving AJ (2009) The GPR55 ligand L-alpha-lysophosphatidylinositol promotes RhoA-dependent Ca2+ signaling and NFAT activation. FASEB J 23(1):183-193. doi: 10.1096/fj.08-108670
12. Henstridge CM, Balenga NA, Schroder R, Kargl JK, Platzer W, Martini L, Arthur S, Penman J, Whistler JL, Kostenis E, Waldhoer M, Irving AJ (2010) GPR55 ligands promote receptor coupling to multiple signalling pathways. Br J Pharmacol 160(3):604-614. doi: 10.1111/j.1476-5381.2009.00625.x
13. Heynen-Genel S, Dahl R, Shi S, Milan L, Hariharan S, Bravo Y, Sergienko E, Hedrick M, Dad S, Stonich D, Su Y, Vicchiarelli M, Mangravita-Novo A, Smith LH, Chung TDY, Sharir H, Barak LS, Abood ME (2010) Screening for Selective Ligands for GPR55 - Agonists. Probe Reports from the Molecular Libraries Program, 2011/11/18 edn., Bethesda, MD. doi:NBK66152 [bookaccession]
14. Huang L, Ramirez JC, Frampton GA, Golden LE, Quinn MA, Pae HY, Horvat D, Liang LJ, DeMorrow S (2011) Anandamide exerts its antiproliferative actions on cholangiocarcinoma by activation of the GPR55 receptor. Lab Invest 91(7):1007-1017. doi: 10.1038/labinvest.2011.62
15. Irving A (2011) New blood brothers: the GPR55 and CB(2) partnership. Cell Res. doi: 10.1038/cr.2011.77
16. Joseph J, Niggemann B, Zaenker KS, Entschladen F (2004) Anandamide is an endogenous inhibitor for the migration of tumor cells and T lymphocytes. Cancer Immunol Immunother 53(8):723-728. doi: 10.1007/s00262-004-0509-9 [doi]
17. Kapur A, Zhao P, Sharir H, Bai Y, Caron MG, Barak LS, Abood ME (2009) Atypical responsiveness of the orphan receptor GPR55 to cannabinoid ligands. J Biol Chem 284(43):29817-29827. doi: 10.1074/jbc.M109.050187
18. Kotsikorou E, Madrigal KE, Hurst DP, Sharir H, Lynch DL, Heynen-Genel S, Milan LB, Chung TD, Seltzman HH, Bai Y, Caron MG, Barak L, Abood ME, Reggio PH (2011) Identification of the GPR55 agonist binding site using a novel set of high-potency GPR55 selective ligands. Biochemistry 50(25):5633-5647. doi: 10.1021/bi200010k
19. Lauckner JE, Jensen JB, Chen HY, Lu HC, Hille B, Mackie K (2008) GPR55 is a cannabinoid receptor that increases intracellular calcium and inhibits M current. Proc Natl Acad Sci U S A 105(7):2699-2704. doi: 10.1073/pnas.0711278105
20. Mitrirattanakul S, Ramakul N, Guerrero AV, Matsuka Y, Ono T, Iwase H, Mackie K, Faull KF, Spigelman I (2006) Site-specific increases in peripheral cannabinoid receptors and their endogenous ligands in a model of neuropathic pain. Pain 126:102-114
21. Oka S, Nakajima K, Yamashita A, Kishimoto S, Sugiura T (2007) Identification of GPR55 as a lysophosphatidylinositol receptor. Biochem Biophys Res Commun 362(4):928-934. doi: 10.1016/j.bbrc.2007.08.078
22. Pertwee RG, Howlett AC, Abood ME, Alexander SP, Di Marzo V, Elphick MR, Greasley PJ, Hansen HS, Kunos G, Mackie K, Mechoulam R, Ross RA (2010) International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB and CB. Pharmacol Rev 62(4):588-631. doi: 10.1124/pr.110.003004
23. Petrosino S, Palazzo E, de Novellis V, Bisogno T, Rossi F, Maione S, Di Marzo V (2007) Changes in spinal and supraspinal endocannabinoid levels in neuropathic rats. Neuropharmacology 52:415-422
24. Pietr M, Kozela E, Levy R, Rimmerman N, Lin YH, Stella N, Vogel Z, Juknat A (2009) Differential changes in GPR55 during microglial cell activation. FEBS Lett 583(12):2071-2076. doi: 10.1016/j.febslet.2009.05.028
25. Pineiro R, Maffucci T, Falasca M (2011) The putative cannabinoid receptor GPR55 defines a novel autocrine loop in cancer cell proliferation. Oncogene 30(2):142-152. doi: 10.1038/onc.2010.417
26. Porter AC, Sauer JM, Knierman MD, Becker GW, Berna MJ, Bao J, Nomikos GG, Carter P, Bymaster FP, Leese AB, Felder CC (2002) Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor. J Pharmacol Exp Ther 301(3):1020-1024
27. Ryberg E, Larsson N, Sjogren S, Hjorth S, Hermansson NO, Leonova J, Elebring T, Nilsson K, Drmota T, Greasley PJ (2007) The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol 152(7):1092-1101. doi: 10.1038/sj.bjp.0707460
28. Scotter EL, Abood ME, Glass M (2010) The endocannabinoid system as a target for the treatment of neurodegenerative disease. Br J Pharmacol 160:480-498
29. Showalter VM, Compton DR, Martin BR, Abood ME (1996) Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): Identification of cannabinoid receptor subtype selective ligands. J Pharmacol Exp Ther 278(3):989-999
30. Staton PC, Hatcher JP, Walker DJ, Morrison AD, Shapland EM, Hughes JP, Chong E, Mander PK, Green PJ, Billinton A, Fulleylove M, Lancaster HC, Smith JC, Bailey LT, Wise A, Brown AJ, Richardson JC, Chessell IP (2008) The putative cannabinoid receptor GPR55 plays a role in mechanical hyperalgesia associated with inflammatory and neuropathic pain. Pain 139(1):225-236. doi: 10.1016/j.pain.2008.04.006
31. Sugiura T, Waku K (2000) 2-Arachidonoylglycerol and the cannabinoid receptors. Chem Phys Lipids 108:89-106
32. 2, disrupts G-protein coupling. J Pharmacol Exp Ther 285(2):651-658
33. Vrecl M, Norregaard PK, Almholt DL, Elster L, Pogacnik A, Heding A (2009) Beta-arrestin-based Bret2 screening assay for the "non"-beta-arrestin binding CB1 receptor. J Biomol Screen 14(4):371-380. doi: 10.1177/ 1087057109333101
34. Walter L, Stella N (2004) Cannabinoids and neuroinflammation. Br J Pharmacol 141(5):775-785. doi: 10.1038/sj.bjp.0705667
35. Whyte LS, Ryberg E, Sims NA, Ridge SA, Mackie K, Greasley PJ, Ross RA, Rogers MJ (2009) The putative cannabinoid receptor GPR55 affects osteoclast function in vitro and bone mass in vivo. Proc Natl Acad Sci U S A 106(38):16511-16516. doi: 10.1073/pnas.0902743106
36. Yin H, Chu A, Li W, Wang B, Shelton F, Otero F, Nguyen DG, Caldwell JS, Chen YA (2009) Lipid G protein-coupled receptor ligand identification using beta-arrestin PathHunter assay. J Biol Chem 284(18):12328-12338. doi: 10.1074/jbc.M806516200